You are here

  • Home
  • Archive
  • Volume 68, Issue 6
  • Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Article metrics

Article menu

Download PDFPDF

XML
Hepatology
Original article
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

 

Online download statistics by month:

Online download statistics by month: October 2018 to November 2023

AbstractFullPdf
Oct 2018806845174
Nov 201838843199
Dec 201833233283
Jan 201923823884
Feb 201920620069
Mar 2019258253107
Apr 201921621078
May 2019471460160
Jun 2019303290132
Jul 2019233224109
Aug 2019155150118
Sep 2019171165100
Oct 201918917774
Nov 201914713583
Dec 201915714773
Jan 202016915780
Feb 202014914686
Mar 202017616198
Apr 202011310576
May 2020122118139
Jun 2020132124205
Jul 2020119115137
Aug 202010187122
Sep 2020132112147
Oct 2020142131139
Nov 2020999284
Dec 2020124119104
Jan 2021135119122
Feb 2021978064
Mar 2021144130100
Apr 202111710875
May 202113412475
Jun 202112411967
Jul 202112111192
Aug 2021928871
Sep 202112511773
Oct 202112812586
Nov 2021169156109
Dec 202114013880
Jan 202211210147
Feb 202213212667
Mar 2022259248120
Apr 202220419388
May 202219918298
Jun 2022230214101
Jul 202213013087
Aug 202212912672
Sep 202215514974
Oct 202213812965
Nov 202211911052
Dec 202213912872
Jan 202313912967
Feb 202315814169
Mar 202314212882
Apr 202313812569
May 2023939559
Jun 202311610950
Jul 202311110265
Aug 202311510844
Sep 202312311763
Oct 202316515978
Nov 202316914370
Total10789103315633